Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Oct 15, 2020 10:00 AM - Oct 16, 2020 4:20 PM

Fort Washington, PA 19034

Combination Products Conference

Session 8: Panel Discussion on Human Factors for Combination Product Development and Closing Remarks

Session Chair(s)

Karthik  Balasubramanian, PhD, MS

Karthik Balasubramanian, PhD, MS

VIce President, CMC & Technical Operations

Verrica Pharmaceuticals, United States

Karl  Saldanha, PhD

Karl Saldanha, PhD

Associate Regulatory Program Director

United States, United States

This session offers the opportunity for industry and FDA Human Factors (HF) leaders to offer their viewpoints and experiences regarding the role of HF in the development of drug-device combination products. Topics discussed will focus on the HF engineering process and its integration within the overall design controls process. In particular, the session will focus on use of formative studies to inform combination product design, as well as key considerations in HF validation study design, execution, and analysis of results. In addition, panelists will discuss the use of comparative/threshold analysis and associated studies. The session will offer the audience an opportunity to interact directly with the panelists and ask questions.

Learning Objective :
  • Identify the role HF engineering plays in combination product development and the design controls process
  • Discuss the intent of formative assessments and how they are performed
  • Recognize key considerations in HF validation study design, execution, and analysis of results
  • Apply use of comparative/threshold analysis and associated studies
  • Define key regulatory expectations for HF in combination products

Speaker(s)

Christina Mendat Mendat, PhD

Panelist

Christina Mendat Mendat, PhD

Human Factors MD, United States

Managing Director

Shannon  Hoste, MS

Panelist

Shannon Hoste, MS

Agilis Consulting Group, United States

President

Paul  Blowers, MA

Panelist

Paul Blowers, MA

AbbVie Inc., United States

Director, Human Factors - Drug Delivery Solutions

Irene Z. Chan, PharmD

Panelist

Irene Z. Chan, PharmD

FDA, United States

Director (Acting), Division of Medication Error Prevention and Analysis 1, OSE,

James  Wabby, MHS

Closing Remarks

James Wabby, MHS

AbbVie, United States

Global Head, Regulatory Affairs, Emerging Technologies and Combination Products

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.